Dorking Surrey, United Kingdom

Jeremy G Vinter


Average Co-Inventor Count = 2.9

ph-index = 2

Forward Citations = 8(Granted Patents)


Location History:

  • Dorking, Surrey RH4 2AQ, GB (1984)
  • Weston, Hitchin, Herts, GB (1985)
  • Dorking, GB (1989)

Company Filing History:


Years Active: 1984-1989

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Jeremy G Vinter: Innovator in Chemotherapeutic Agents

Introduction

Jeremy G Vinter is a notable inventor based in Dorking, Surrey, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of chemotherapeutic agents. With a total of 3 patents to his name, Vinter's work focuses on innovative methods for treating viral infections.

Latest Patents

Vinter's latest patents include a method of treating or preventing viral infections, specifically targeting rhinovirus infections. This method involves the administration of an effective amount of a 2-phenyltetralin derivative or a heterocyclic analogue thereof. Additionally, he has developed pharmaceutical compositions containing these compounds, along with some novel compounds. Another patent involves imidazole derivatives, which are compounds characterized by specific formulas that include halogen atoms and other defined elements.

Career Highlights

Throughout his career, Vinter has worked with reputable companies, including Burroughs Wellcome Co. His experience in the pharmaceutical industry has allowed him to contribute to significant advancements in drug development and treatment methodologies.

Collaborations

Vinter has collaborated with notable individuals in his field, including Harold Francis Hodson and John Frederick Batchelor. These collaborations have likely enriched his research and innovation efforts.

Conclusion

Jeremy G Vinter's contributions to the field of chemotherapeutic agents highlight his role as an influential inventor. His innovative approaches to treating viral infections demonstrate the importance of continued research and development in pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…